Exploration of key clinical trial data and real-world evidence on dupilumab in asthma and COPD presented at the ERS and CHEST ...
Once limited to nonspecific anti-inflammatory therapies, expanding treatment options for atopic dermatitis are allowing therapy to be individualized.
GlobalData on MSN
GSK obtains FDA approval for Exdensur in severe asthma
Exdensur is now the first twice-yearly add-on maintenance therapy approved for use in severe eosinophilic asthma.
Patients with chronic spontaneous urticaria (CSU) often experience impaired QOL, especially when antihistamines, the standard ...
A multicentre clinical trial led by a researcher from the University of Sherbrooke will test a new therapeutic approach to moderate asthma. The study will include 150 patients, including 50 in Quebec, ...
We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) ...
JAK inhibitor treatment is not associated with stunted growth in children with common inflammatory diseases, according to a ...
Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is initiating a Phase 2 study ...
Patients with eosinophilic granulomatosis with polyangiitis who received 2 years of treatment with the interleukin-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback